The proposition has been put that the lack of treatment and fatal outcome are contributing factors to suggest it is likely an FDA trial will proceed, no-one suggests CVac is going to be "waved through".
As for the article, the drug in question seems principally spoken of as a chemo-sensitising agent to multiply the effect of the chemo agent a hundred-fold.
This enables one hundredth of the chemo dose to be given, with the same outcome - one which so far does not appear to comprise an effective or effective enough "cure".
There doesn't seem to be an obvious adverse outcome for CVac that such a drug is in development for different aspects of treatment of the same cancer.
The article also mentions the drug in relation to prostate cancer - didn't seem to have slowed down Dendreon.
With the money spent on cancer research world-wide, there must be a tremendous number of compounds being researched.
PRR Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)